Apolipoproteínas B e A-I: fatores de risco cardiovascular?

Forti, Neusa Assumpta; Diament, J

doi:10.1590/s0104-42302007000300029

Cited by 10 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[31, 33, 47–49], components of the lipid profile (lipoprotein[a], apolipoproteins, triacylglycerides, etc.) [29, 50, 51], and elements linked to prothrombotic states (fibrinogen, homocysteine, D-dimer, etc.) [35, 37, 52].…”

Section: Cardiovascular Risk Factors: Classic Versus Novel (Table 1)mentioning

confidence: 99%

C-Reactive Protein: Clinical and Epidemiological Perspectives

Salazar

Martínez

Chávez-Castillo

et al. 2014

Cardiology Research and Practice

View full text Add to dashboard Cite

An important etiopathogenic component of cardiovascular disease is atherosclerosis, with inflammation being an essential event in the pathophysiology of all clinical pictures it comprises. In recent years, several molecules implicated in this process have been studied in order to assess cardiovascular risk in both primary and secondary prevention. C-reactive protein is a plasmatic protein of the pentraxin family and an acute phase reactant, very useful as a general inflammation marker. Currently, it is one of the most profoundly researched molecules in the cardiovascular field, yet its clinical applicability regarding cardiovascular risk remains an object of discussion, considered by some as a simple marker and by others as a true risk factor. In this sense, numerous studies propose its utilization as a predictor of cardiovascular risk through the use of high-sensitivity quantification methods for the detection of values <1 mg/L, following strict international guidelines. Increasing interest in these clinical findings has led to the creation of modified score systems including C-reactive protein concentrations, in order to enhance risk scores commonly used in clinical practice and offer improved care to patients with cardiovascular disease, which remains the first cause of mortality at the worldwide, national, and regional scenarios.

show abstract

Section: Cardiovascular Risk Factors: Classic Versus Novel (Table 1)mentioning

confidence: 99%

C-Reactive Protein: Clinical and Epidemiological Perspectives

Salazar

Martínez

Chávez-Castillo

et al. 2014

Cardiology Research and Practice

View full text Add to dashboard Cite

show abstract

“…The ApoB/ApoA ratio is identified in studies as a predictive risk marker for atherosclerosis and cardiovascular disease, considering that ApoB represents the atherogenic lipid fraction. Therefore, the balance of cholesterol transport must be maintained with ApoB/ApoA values below 0.9 for men and 0.8 for women 29 . As the control of atherogenesis involves the modulation of oxidative stress, supplementation with astaxanthin is promising, according to the experiment mentioned previously.…”

Section: Human Studiesmentioning

confidence: 99%

Astaxanthin supplementation extracted from Haematococcus pluvialis on clinical parameters associated with chronic diseases and metabolic syndrome / Suplementação de astaxantina extraída de Haematococcus pluvialis sobre os parâmetros clínicos associados com doenças crônicas e síndrome metabólica

Altoé¹,

Paes²,

Cirino³

et al. 2022

BJDV

View full text Add to dashboard Cite

Introduction: astaxanthin is a carotenoid compound found in marine organisms that, according to several studies, has significantly increased antioxidant properties, with possible benefits for the prevention and treatment of chronic diseases and metabolic syndrome. Objective: to indicate the possible biological effects of astaxanthin, as well as its forms of prescription and possible benefits for the prevention and treatment of chronic diseases and metabolic syndrome. Method: integrative review of clinical experimental studies, mainly, but of some pre-clinical studies, also published since 2000. The searches were carried out in the following databases: Pubmed, SciELO and Semantic Scholar. Results: the results indicated doses between 0.5 and 21.6mg/day, for a period from 2 weeks to 12 months, involving volunteers aged between 8 and 85 years, both genders. Supplements with astaxanthin indicated the ability to reduce oxidative stress, as well as biochemical parameters in the blood, such as low-density lipoprotein, total cholesterol, fasting glucose, triglycerides, glycated hemoglobin and others. The bioactive substance is also associated with a reduction in blood pressure, increased blood operations of high-density lipoprotein and adiponectin, reinforcing the hypothesis that astaxanthin is promising, as an aid in the prevention and treatment of chronic diseases and metabolic syndrome. Conclusion: astaxanthin appears to be a complementary and innovative element for the prevention and treatment of chronic diseases and metabolic syndrome. However, no supplement will have a “miraculous” effect and will replace with constant changes in lifestyle, including healthy eating. The antioxidant effects of astaxanthin were confirmed and associated with the most varied metabolic and clinical outcomes. However, due to the reduced amount of evidence and heterogeneity of variables, further research is needed.

show abstract

“…As apolipoproteínas (apo) são a parte proteica das lipoproteínas. São responsáveis pelo fortalecimento de sua estrutura e que têm diversas finalidades no metabolismo lipídico (FORTI; DIAMENT, 2007). Em razão do alto custo e da pequena informação clínica que essas proteínas fornecem, sua dosagem não é incluída nos exames básicos de rotina laboratorial para avaliação de riscos cardiovasculares (BARTER et al, 2006;WALLDIUS;JUNGNER, 2004).…”

Section: Lipídeos E Lipoproteínasunclassified

Análise comparativa da utilização da metodologia de Friedewald e a de Martin na avaliação de perfil lipídico em pacientes do centro de atendimento comunitário do UNICEUB (CAC) / Comparative analysis of the use of the Friedewald and Martin methodology in the lipid profile assessment in patients at the UNICEUB community care center (CAC)

Mendes¹,

Azevedo²,

Andrade³

2021

BJDV

View full text Add to dashboard Cite

show abstract

Apolipoproteínas B e A-I: fatores de risco cardiovascular?

Cited by 10 publications

References 30 publications

C-Reactive Protein: Clinical and Epidemiological Perspectives

C-Reactive Protein: Clinical and Epidemiological Perspectives

Contact Info

Product

Resources

About